C. W. Yde

发表

Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.

A. Lykkesfeldt, A. M. Pedersen, S. Thrane, 2014, International journal of oncology.

Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study

F. Nielsen, H. Poulsen, J. Brennum, 2020, Molecular oncology.

1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells

A. Lykkesfeldt, J. Lundqvist, C. W. Yde, 2014, Steroids.

The regulatory β-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis

D. Meek, B. Guerra, B. Olsen, 2008, Oncogene.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

A. Laenkholm, B. Rasmussen, A. Duun-Henriksen, 2014, Oncogene.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

A. Lykkesfeldt, J. Lundqvist, A. M. Pedersen, 2015, International journal of oncology.

Ultra-fast detection and quantification of nucleic acids by amplification-free fluorescence assay.

Hanlee P. Ji, G. Pruijn, V. Birkedal, 2020, The Analyst.

Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study

F. Nielsen, H. Poulsen, J. Brennum, 2019, Oncotarget.

Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells.

J. E. Rasmussen, O. Issinger, B. Guerra, 2007, Organic & biomolecular chemistry.

Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1.

O. Issinger, C. W. Yde, C. Yde, 2006, International journal of oncology.